Literature DB >> 31769140

B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure.

Nicholas Wettersten1,2, Yu Horiuchi1,2, Dirk J van Veldhuisen3, Christian Mueller4, Gerasimos Filippatos5, Richard Nowak6, Christopher Hogan7, Michael C Kontos8, Chad M Cannon9, Gerhard A Müeller10, Robert Birkhahn11, Pam Taub1, Gary M Vilke12, Olga Barnett13, Kenneth McDonald14,15, Niall Mahon14, Julio Nuñez16, Carlo Briguori17, Claudio Passino18, Patrick T Murray14, Alan Maisel1.   

Abstract

AIMS: In acute heart failure (AHF), relationships between changes in B-type natriuretic peptide (BNP) and worsening renal function (WRF) and its prognostic implications have not been fully determined. We investigated the relationship between WRF and a decrease in BNP with in-hospital and 1-year mortality in AHF. METHODS AND
RESULTS: The Acute Kidney Injury NGAL Evaluation of Symptomatic heart faIlure Study (AKINESIS) was a prospective, international, multicentre study of AHF patients. Severe WRF (sWRF) was a sustained increase of ≥44.2 μmol/L (0.5 mg/dL) or ≥50% in creatinine, non-severe WRF (nsWRF) was a non-sustained increase of ≥26.5 μmol/L (0.3 mg/dL) or ≥50% in creatinine, and WRF with clinical deterioration was nsWRF with renal replacement therapy, inotrope use, or mechanical ventilation. Decreased BNP was defined as a ≥30% reduction in the last measured BNP compared to admission BNP. Among 814 patients, the incidence of WRF was not different between patients with or without decreased BNP (nsWRF: 33% vs. 31%, P = 0.549; sWRF: 11% vs. 9%, P = 0.551; WRF with clinical deterioration: 8% vs. 10%, P = 0.425). Decreased BNP was associated with better in-hospital and 1-year mortality regardless of WRF, while WRF was associated with worse outcomes only in patients without decreased BNP. In multivariate Cox regression analysis, decreased BNP, sWRF, and WRF with clinical deterioration were significantly associated with 1-year mortality.
CONCLUSIONS: Decreased BNP was associated with better in-hospital and long-term outcomes. WRF was only associated with adverse outcomes in patients without decreased BNP.
© 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology.

Entities:  

Keywords:  Acute heart failure; B-type natriuretic peptide; Mortality; Worsening renal function

Mesh:

Substances:

Year:  2019        PMID: 31769140     DOI: 10.1002/ejhf.1627

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  4 in total

Review 1.  Biomarkers in Acute Heart Failure: Diagnosis, Prognosis, and Treatment.

Authors:  Nicholas Wettersten
Journal:  Int J Heart Fail       Date:  2021-02-15

2.  Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure.

Authors:  Takayuki Yamada; Hiroki Ueyama; Nitin Chopra; Takahiro Yamaji; Kengo Azushima; Ryu Kobayashi; Sho Kinguchi; Shingo Urate; Toru Suzuki; Eriko Abe; Yusuke Saigusa; Hiromichi Wakui; Paulina Partridge; Alfred Burger; Claudio A Bravo; Maria A Rodriguez; Juan Ivey-Miranda; Kouichi Tamura; Jeffery Testani; Steven Coca
Journal:  Kidney Int Rep       Date:  2020-07-02

Review 3.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

4.  Clinical significance of the long non-coding RNA NEAT1/miR-129-5p axis in the diagnosis and prognosis for patients with chronic heart failure.

Authors:  Haohua Zhang; Nianli Zhang; Wenbin Jiang; Xiaoqin Lun
Journal:  Exp Ther Med       Date:  2021-03-19       Impact factor: 2.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.